An observational study in Myocardial Infarction, sponsored by Chiesi USA, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Chiesi USA, Inc. (part of Chiesi Farmaceutici S.p.A.) · Observational
Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cang…
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.
Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 32nd largest by enrollment of the 136 observational ones that give a count, is one of 13 that started in 2019, is one of 136 observational ones, and was the 338th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 40+
Massachusetts General Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 18+
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 61 · Phase 3 76 · Phase 4 25
First in 1988; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,050 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 160 across the 301 interventional studies, 514 across the 136 observational. Of the 337 that completed or were terminated, 132 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 440 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chiesi USA, Inc., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
This is the only study on the registry with Chiesi USA, Inc. as lead sponsor.
Chiesi Farmaceutici S.p.A. has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
18 of the studies in Myocardial Infarction with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05371470Mayo ClinicVoice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation | 2026-11 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT04521699Mayo ClinicExamination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk. | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 440 studies in Myocardial Infarction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
The CAMEO registry is a multicenter observational registry that will collect information on approximately 5,050 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry.
Phase 1: Each site will abstract data from the medical record for the first 50 patients meeting the inclusion and exclusion criteria treated at the hospital within 4 months prior to study initiation or during the study period.
Phase 2: After Phase 1, all cangrelor-treated patients meeting the inclusion and exclusion criteria will be entered into the registry, and we will begin sampling non-cangrelor patients in a 2:1 cangrelor: non-cangrelor ratio (Phase 2) up to 3000 patients.
Phase 3: We will work with sites on a quality improvement initiative with the current sites to 1) continue enrollment of an additional 2,000 patients; 2) provide feedback reports to both the sites and operators about the use and administration of cangrelor to patients they are treating; 3) utilize a pharmacist-based group with representatives from each site to identify opportunities to improve use of cangrelor according to the established treatment strategy.
≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI.
Phase 1 Inclusion Criteria:
For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI.
Phase 2 Inclusion Criteria:
Subsequent patients are eligible to be entered in the registry if they are ≥ 18 years of age and underwent coronary angiography for a STEMI or NSTEMI and meet at least 1 of the following criteria:
The patient was hospitalized for STEMI and met one of the following inclusion criteria:
OR
The patient was hospitalized for NSTEMI and met one of the following inclusion criteria:
Exclusion Criteria: If the patient does not meet the inclusion criteria for either Phase.
Phase 3 Eligibility Criteria:
The Phase 3 portion of the CAMEO registry will focus on launching local site quality improvement initiatives with the goal of optimizing cangrelor usage according to FDA-approved established treatment strategy. Enrollment for the registry will be extended for an additional two years to include an additional 2,000 patients in this phase of the registry. The inclusion criteria of these patients will be the same as in Phase 2 (see section 3.3.2). We will also capture which patients are cared for at each site by individual operators. Operator-level data will be de-identified, and each operator will be assigned an operator ID. Sites will be asked to maintain a crosswalk for operator ID, and complete an operator characteristics survey. The operator characteristics survey will ask questions around age, sex, and other relevant operator characteristics, and will be used in the analysis phase in aggregate. Operators will not be directly identified and the analytics center will not have access to the crosswalk, which will be maintained at the site.
We will identify a pharmacist representative at each site to form a pharmacist-based group who meets monthly to identify strategies to improve processes at each site and to improve use of cangrelor in the MI population according to the established treatment strategy. We will present quarterly feedback reports to the sites that include data regarding the use of cangrelor according to the following parameters: 1) administration of both a bolus and infusion; 2) appropriate timing between infusion and initiation of oral PY212 inhibitor therapy; 3) and administration of the infusion based on clinical trial data and dose package labeling for patients who are able to be transitioned to oral P2Y12 inhibitor therapy shortly after PCI.
Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
The number of Antiplatelet medications used during hospitalization
Antiplatelet use, including switching and discontinuation will be measured by medical record report. The medical record report will include medication start and stop dates and times.
Time frame: The time frame is hospitalization through discharge, approximately 3 days
Number of bleeding events during hospitalization as measured by medical record report
Bleeding event entered from the medical record report.
Time frame: The time frame is hospitalization, up to 7 days post discharge
Plan to share: No — There is not a current plan to share IPD.
Ran from Oct 2019 to primary completion in Nov 2025, 73 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2025 → Nov 2025 and completion Jun 2025 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cang…
Rymer JA, Page C, Alhanti B, Narcisse D, Washam J, Ang L, Bach R, Wimmer N, Kochar A, El-Sabae H, Angiolillo DJ, Bhatt D, Chaturvedi A, Waksman R. TCT-299 cang…
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.